SUPN
Supernus Pharmaceuticals Inc
NASDAQ: SUPN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$48.55
-0.29% today
Updated 2026-04-29
Market cap
$2.80B
P/E ratio
—
P/S ratio
3.89x
EPS (TTM)
$-0.68
Dividend yield
—
52W range
$29 – $60
Volume
0.7M
Supernus Pharmaceuticals Inc (SUPN) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-21.7%
Last 4 quarters
Revenue YoY growth
+21.5%
Most recent quarter
EPS YoY growth
+60.9%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.0%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-15.4%
2025-11-04
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-03 | $0.88 | +115.1% | $55.09 | $55.58 | +0.9% |
| 2025-11-04 | $-0.80 | -671.4% | $55.70 | $47.11 | -15.4% |
| 2025-08-05 | $0.40 | -16.7% | $37.05 | $42.44 | +14.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.41 | $0.88 | +115.1% | $211.57M | +21.5% |
| 2025-09-30 | $0.14 | $-0.80 | -671.4% | $192.10M | +9.3% |
| 2025-06-30 | $0.48 | $0.40 | -16.7% | $165.45M | -1.7% |
| 2025-03-31 | $0.38 | $0.44 | +14.8% | $149.82M | +4.3% |
| 2024-12-31 | $0.52 | $0.55 | +5.4% | $174.16M | +6.0% |
| 2024-09-30 | $0.44 | $0.69 | +56.8% | $175.69M | +14.2% |
| 2024-06-30 | $0.31 | $0.36 | +16.1% | $168.32M | +24.2% |
| 2024-03-31 | $0.38 | $0.26 | -31.6% | $143.64M | -6.6% |
| 2023-12-31 | $0.55 | $0.89 | +61.8% | $164.31M | — |
| 2023-09-30 | $0.08 | $0.24 | +200.0% | $153.88M | — |
| 2023-06-30 | $-0.23 | $-0.02 | +91.3% | $135.56M | — |
| 2023-03-31 | $0.17 | $0.29 | +70.6% | $153.76M | — |
Frequently asked questions
Has Supernus Pharmaceuticals Inc beaten earnings estimates?
Supernus Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -21.7% over the last 4 quarters.
How does SUPN stock react to earnings?
SUPN stock has moved an average of +0.0% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Supernus Pharmaceuticals Inc's revenue growth rate?
Supernus Pharmaceuticals Inc reported year-over-year revenue growth of +21.5% in its most recent quarter, with EPS growing +60.9% year-over-year.